cdx-1140
Peptideexperimental
Clinical trial activity
12 trials · 13 clinical orgs · 0 marketing orgs
Phase 1
9
Phase 2
6
Phase 3
0
Phase 4
0
Earliest trial started Dec 1, 2017 (NCT03329950)
Timeline
Indications
Studied for
- Basal Cell Carcinoma · Phase 1
- Bile Duct Neoplasms · Phase 1/Phase 2
- Biliary Tract Neoplasms · Phase 1/Phase 2
- Breast Neoplasms · Phase 1
- Carcinoma · Phase 1
- Carcinoma, Merkel Cell · Phase 1
- Carcinoma, Non-Small-Cell Lung · Phase 1/Phase 2
- Carcinoma, Renal Cell · Phase 1
- Carcinoma, Squamous Cell · Phase 2
- Carcinoma, Transitional Cell · Phase 1
- Cholangiocarcinoma · Phase 1
- Colorectal Neoplasms · Phase 1
- Endometrial Neoplasms · Phase 2
- Esophageal Neoplasms · Phase 1
- Fallopian Tube Neoplasms · Phase 2
- Hamartoma · Phase 2
- Head and Neck Neoplasms · Phase 1
- Laryngeal Neoplasms · Phase 2
- Leukemia, Lymphocytic, Chronic, B-Cell · Phase 1
- Liver Neoplasms · Phase 1
- Lung Neoplasms · Phase 1/Phase 2
- Lymphoma · Phase 1
- Lymphoma, B-Cell, Marginal Zone · Phase 1
- Lymphoma, Follicular · Phase 1
- Lymphoma, Large B-Cell, Diffuse · Phase 1
- Lymphoma, Mantle-Cell · Phase 1
- Lymphoma, Non-Hodgkin · Phase 1
- Melanoma · Phase 1/Phase 2
- Mouth Neoplasms · Phase 2
- Nasopharyngeal Carcinoma · Phase 2
- Neoplasms · Phase 1
- Osteosarcoma · Phase 1
- Ovarian Neoplasms · Phase 2
- Pancreatic Neoplasms · Phase 2
- Sarcoma · Phase 1
- Squamous Cell Carcinoma of Head and Neck · Phase 2
- Stomach Neoplasms · Phase 1
- Tissues · Phase 1
- Waldenstrom Macroglobulinemia · Phase 1
Mechanism of action
Tumor necrosis factor receptor superfamily member 5 agonist
CD40 inhibitor
Chemistry & pharmacology
- Inorganic
- No
- Polymer
- No
- Multi-specific
- No
Oral
No
Parenteral
No
Topical
No
Sources
- ChEMBLCHEMBL4297721 ↗
Clinical trials
| NCT ID | Phase | Start date | Sponsor(s) |
|---|---|---|---|
| NCT06980038 | Phase 2 | Nov 21, 2025 | Johns Hopkins University, National Cancer Institute (NCI) |
| NCT05849480 | Phase 1/Phase 2 (Phase 2) | Jan 3, 2024 | National Cancer Institute (NCI) |
| NCT05231122 | Phase 2 | Jan 15, 2023 | Celldex Therapeutics, Merck, National Cancer Institute (NCI), State University of New York, Buffalo |
| NCT05484011 | Phase 1 | Dec 31, 2022 | Celldex Therapeutics, HiberCell, Inc., University of Pennsylvania |
| NCT05349890 | Phase 1 | Oct 15, 2022 | Celldex Therapeutics, Providence Health & Services |
| NCT05029999 | Phase 1 | Dec 31, 2021 | Celldex Therapeutics, Gateway for Cancer Research, The University of Texas, Dallas |
| NCT04536077 | Phase 2 | Jan 31, 2021 | Celldex Therapeutics, Washington University in St. Louis |
| NCT04491084 | Phase 1/Phase 2 (Phase 2) | Jan 1, 2021 | Celldex Therapeutics, Yeshiva University |
| NCT04616248 | Phase 1 | Dec 1, 2020 | State University of New York, Buffalo |
| NCT04520711 | Phase 1 | Oct 1, 2020 | Providence Health & Services |
| NCT04364230 | Phase 1/Phase 2 (Phase 2) | May 8, 2020 | Celldex Therapeutics, University of Virginia |
| NCT03329950 | Phase 1 | Dec 1, 2017 | Celldex Therapeutics |
Showing 12 of 12 trials
Page 1 / 1
Organizations
Research & Development (13)
| Organization | Org type | Trials | As lead sponsor | Phases | Earliest year |
|---|---|---|---|---|---|
| Celldex Therapeutics | For profit | 8 | 1 | 2 | 2017 |
| National Cancer Institute (NCI) | Government | 3 | 2 | 1 | 2023 |
| Providence Health & Services | Academic/Hospital | 2 | 2 | 1 | 2020 |
| State University of New York, Buffalo | Academic/Hospital | 2 | 2 | 2 | 2020 |
| Gateway for Cancer Research | Academic/Hospital | 1 | 0 | 1 | 2021 |
| HiberCell, Inc. | For profit | 1 | 1 | 1 | 2022 |
| Johns Hopkins University | Academic/Hospital | 1 | 0 | 1 | 2025 |
| Merck | For profit | 1 | 0 | 1 | 2023 |
| The University of Texas, Dallas | Academic/Hospital | 1 | 1 | 1 | 2021 |
| University of Pennsylvania | Academic/Hospital | 1 | 0 | 1 | 2022 |
| University of Virginia | Academic/Hospital | 1 | 1 | 1 | 2020 |
| Washington University in St. Louis | Academic/Hospital | 1 | 1 | 1 | 2021 |
| Yeshiva University | Academic/Hospital | 1 | 1 | 1 | 2021 |
13 organizations
Page 1 / 1